| 2024 |
| 04/26 | 356 | 362 | 356 | 360 | 0% | 27,900 | 92億790万 | +2.86% |
| 04/25 | 353 | 360 | 353 | 360 | +1.12% | 41,900 | 92億790万 | +2.56% |
| 04/24 | 355 | 359 | 353 | 356 | +0.28% | 31,700 | 91億559万 | +1.42% |
| 04/23 | 363 | 363 | 353 | 355 | -1.39% | 24,600 | 90億8001万 | +1.14% |
| 04/22 | 346 | 363 | 346 | 360 | +4.35% | 72,100 | 92億790万 | +2.27% |
| 04/19 | 347 | 354 | 339 | 345 | -1.15% | 114,000 | 88億2423万 | -1.99% |
| 04/18 | 350 | 356 | 348 | 349 | -1.69% | 63,700 | 89億2654万 | -1.41% |
| 04/17 | 366 | 366 | 355 | 355 | -1.93% | 63,500 | 90億8001万 | -0.56% |
| 04/16 | 351 | 364 | 350 | 362 | +2.55% | 104,500 | 92億5905万 | +0.84% |
| 04/15 | 357 | 358 | 350 | 353 | -2.22% | 52,500 | 90億2885万 | -2.75% |
| 04/12 | 360 | 363 | 350 | 361 | +0.28% | 121,000 | 92億3347万 | -1.1% |
| 04/11 | 363 | 363 | 346 | 360 | 0% | 135,300 | 92億790万 | -0.55% |
| 04/10 | 343 | 360 | 342 | 360 | +4.65% | 97,100 | 92億790万 | 0% |
| 04/09 | 341 | 347 | 339 | 344 | +1.47% | 54,300 | 87億9866万 | -3.64% |
| 04/08 | 340 | 340 | 331 | 339 | +1.19% | 80,200 | 86億7077万 | -4.51% |
| 04/05 | 16:00 パイプライン「TLG-005」の軽度認知症(MCI)の特定臨床研究における被験者組入れ完了のお知らせ |
| 04/05 | 316 | 335 | 313 | 335 | +3.72% | 82,700 | 85億6846万 | -5.1% |
| 04/04 | 318 | 330 | 318 | 323 | +1.57% | 97,500 | 82億6153万 | -8.24% |
| 04/03 | 328 | 328 | 316 | 318 | -3.64% | 83,000 | 81億3364万 | -9.66% |
| 04/02 | 348 | 348 | 330 | 330 | -5.44% | 94,700 | 84億4057万 | -5.98% |
| 04/01 | 355 | 356 | 348 | 349 | -1.41% | 55,400 | 89億2654万 | -0.29% |
| 03/29 | 347 | 356 | 346 | 354 | +2.31% | 36,700 | 90億5443万 | +2.02% |
| 03/28 | 351 | 354 | 344 | 346 | -1.7% | 77,800 | 88億4981万 | +0.29% |
| 03/27 | 358 | 360 | 351 | 352 | -0.56% | 83,700 | 90億328万 | +2.92% |
| 03/26 | 366 | 368 | 354 | 354 | -3.8% | 103,500 | 90億5443万 | +4.12% |
| 03/25 | 379 | 385 | 365 | 368 | -1.87% | 145,500 | 94億1252万 | +9.2% |
| 03/22 | 373 | 376 | 358 | 375 | +1.08% | 169,900 | 95億9156万 | +12.95% |
| 03/21 | 372 | 383 | 366 | 371 | +2.2% | 202,400 | 94億8925万 | +13.46% |
| 03/19 | 16:00 令和5年度女性のためのフェムテック開発支援・普及促進事業における助成事業への採択について |
| 03/19 | 373 | 377 | 356 | 363 | -2.68% | 245,200 | 92億8463万 | +12.38% |
| 03/18 | 368 | 378 | 361 | 373 | +1.08% | 237,800 | 95億4040万 | +16.56% |
| 03/15 | 397 | 398 | 365 | 369 | -6.82% | 356,900 | 94億3809万 | +16.04% |
| 03/14 | 430 | 431 | 381 | 396 | -6.6% | 901,300 | 101億2869万 | +25.32% |
| 03/13 | 407 | 475 | 398 | 424 | +7.34% | 3,442,700 | 108億4486万 | +35.03% |
| 03/12 | 499 | 511 | 390 | 395 | -15.42% | 2,554,000 | 101億311万 | +26.6% |
| 03/11 | 467 | 467 | 467 | 467 | +20.67% | 66,400 | 119億4469万 | +51.13% |
| 03/08 | 387 | 387 | 387 | 387 | +26.06% | 43,400 | 98億9849万 | +27.3% |
| 03/07 | 16:00 業績予想の修正に関するお知らせ |
| 03/07 | 16:00 ロート製薬株式会社との知的財産権実施許諾契約締結についてのお知らせ |
| 03/07 | 318 | 330 | 302 | 307 | +2.68% | 281,500 | 78億5229万 | +1.32% |
| 03/06 | 16:00 令和5年度TOKYO戦略的イノベーション促進事業における助成事業への採択について |
| 03/06 | 289 | 301 | 289 | 299 | +2.75% | 48,100 | 76億4767万 | -1.97% |
| 03/05 | 291 | 296 | 283 | 291 | -0.68% | 35,700 | 74億4305万 | -5.21% |
| 03/04 | 293 | 302 | 292 | 293 | 0% | 32,600 | 74億9420万 | -5.18% |
| 03/01 | 302 | 303 | 289 | 293 | -2.98% | 79,800 | 74億9420万 | -6.09% |
| 02/29 | 320 | 320 | 299 | 302 | -4.73% | 52,800 | 77億2440万 | -3.82% |
| 02/28 | 307 | 320 | 306 | 317 | +2.59% | 113,600 | 81億806万 | +0.63% |
| 02/27 | 293 | 314 | 293 | 309 | +6.19% | 170,500 | 79億344万 | -2.22% |
| 02/26 | 278 | 292 | 273 | 291 | +4.68% | 116,000 | 74億4305万 | -8.2% |
| 02/22 | 296 | 336 | 271 | 278 | -6.08% | 987,700 | 71億1054万 | -12.58% |
| 02/21 | 286 | 319 | 283 | 296 | +2.78% | 221,600 | 75億7094万 | -7.5% |
| 02/20 | 16:00 研究論文「屋外で過ごす時間の増加に伴う、COVID-19パンデミックを受けた眼軸長伸長の鈍化」 発表についてのお知らせ |
| 02/20 | 292 | 295 | 284 | 288 | -0.35% | 75,900 | 73億6632万 | -10.56% |
| 02/19 | 275 | 291 | 275 | 289 | +5.09% | 123,600 | 73億9189万 | -10.8% |
| 02/16 | 256 | 281 | 256 | 275 | +9.13% | 211,200 | 70億3381万 | -15.64% |
| 02/15 | 261 | 261 | 252 | 252 | -3.08% | 67,600 | 64億4553万 | -23.17% |
| 02/14 | 273 | 281 | 258 | 260 | -4.41% | 111,800 | 66億5015万 | -21.45% |
| 02/13 | 16:00 2024年3月期第3四半期決算説明資料 |
| 02/13 | 16:00 2024年3月期第3四半期決算短信〔日本基準〕(非連結) |
| 02/13 | 271 | 281 | 263 | 272 | +0.74% | 177,100 | 69億5708万 | -18.81% |
| 02/09 | 12:00 パイプライン「TLM-007」の特定臨床研究についてのお知らせ |
| 02/09 | 255 | 285 | 255 | 270 | -17.18% | 578,100 | 69億592万 | -19.88% |
| 02/08 | 16:00 参天製薬株式会社との基本合意契約解約についてのお知らせ |
| 02/08 | 16:00 契約損失引当金の計上および業績予想の修正に関するお知らせ |
| 02/08 | 332 | 334 | 326 | 326 | -2.4% | 40,200 | 83億3826万 | -4.12% |
| 02/07 | 344 | 344 | 326 | 334 | -1.76% | 58,900 | 85億4288万 | -1.76% |
| 02/06 | 352 | 352 | 339 | 340 | -4.76% | 68,000 | 86億9635万 | 0% |
| 02/05 | 350 | 359 | 343 | 357 | +4.39% | 47,000 | 91億3116万 | +5.31% |
| 02/02 | 343 | 349 | 342 | 342 | -0.29% | 30,800 | 87億4750万 | +1.48% |
| 02/01 | 351 | 356 | 343 | 343 | -3.38% | 36,600 | 87億7308万 | +2.39% |
| 01/31 | 351 | 357 | 344 | 355 | +1.14% | 60,700 | 90億8001万 | +6.61% |
| 01/30 | 353 | 366 | 350 | 351 | -0.57% | 70,800 | 89億7770万 | +6.04% |
| 01/29 | 357 | 357 | 350 | 353 | +0.86% | 53,000 | 90億2885万 | +6.97% |
| 01/26 | 352 | 360 | 346 | 350 | -2.51% | 94,200 | 89億5212万 | +6.71% |
| 01/25 | 339 | 367 | 332 | 359 | +5.9% | 296,400 | 91億8232万 | +9.79% |
| 01/24 | 338 | 343 | 337 | 339 | +0.3% | 9,100 | 86億7077万 | +3.99% |
| 01/23 | 338 | 347 | 337 | 338 | +0.9% | 71,100 | 86億4519万 | +4% |
| 01/22 | 324 | 338 | 323 | 335 | +4.04% | 51,800 | 85億6176万 | +3.08% |
| 01/19 | 324 | 329 | 320 | 322 | -0.92% | 52,300 | 82億2951万 | -0.92% |
| 01/18 | 328 | 328 | 322 | 325 | -0.31% | 24,400 | 83億618万 | -0.31% |
| 01/17 | 340 | 340 | 326 | 326 | -3.55% | 47,300 | 83億3174万 | -0.31% |
| 01/16 | 345 | 351 | 338 | 338 | -1.74% | 49,200 | 86億3843万 | +2.74% |
| 01/15 | 334 | 344 | 334 | 344 | +3.61% | 41,800 | 87億9178万 | +3.93% |
| 01/12 | 340 | 341 | 331 | 332 | -1.19% | 27,500 | 84億8509万 | -0.3% |
| 01/11 | 338 | 343 | 336 | 336 | -0.3% | 49,900 | 85億8732万 | 0% |
| 01/10 | 340 | 344 | 337 | 337 | -0.88% | 65,900 | 86億1287万 | -0.59% |
| 01/09 | 342 | 349 | 338 | 340 | +1.49% | 49,200 | 86億8955万 | -0.58% |
| 01/05 | 344 | 344 | 333 | 335 | -1.76% | 75,300 | 85億6176万 | -2.62% |
| 01/04 | 335 | 347 | 329 | 341 | +1.79% | 102,300 | 87億1510万 | -1.73% |
| 2023 |
| 12/29 | 334 | 341 | 323 | 335 | +0.3% | 108,800 | 85億6176万 | -4.29% |
| 12/28 | 305 | 334 | 304 | 334 | +8.79% | 123,600 | 85億3620万 | -5.38% |
| 12/27 | 294 | 312 | 290 | 307 | +3.37% | 216,600 | 78億4615万 | -13.76% |
| 12/26 | 292 | 299 | 291 | 297 | +1.02% | 132,800 | 75億9057万 | -17.73% |
| 12/25 | 298 | 301 | 290 | 294 | -2.33% | 149,400 | 75億1390万 | -19.45% |
| 12/22 | 310 | 312 | 298 | 301 | -1.31% | 177,100 | 76億9280万 | -18.65% |
| 12/21 | 313 | 314 | 305 | 305 | -4.98% | 148,900 | 77億9503万 | -18.45% |
| 12/20 | 318 | 324 | 315 | 321 | +0.94% | 104,800 | 82億395万 | -15.3% |
| 12/19 | 314 | 326 | 314 | 318 | 0% | 157,000 | 81億2728万 | -16.97% |
| 12/18 | 320 | 323 | 306 | 318 | -3.05% | 176,500 | 81億2728万 | -18.04% |
| 12/15 | 330 | 343 | 318 | 328 | -0.3% | 161,300 | 83億8286万 | -16.75% |
| 12/14 | 338 | 341 | 320 | 329 | -1.2% | 111,500 | 84億841万 | -17.54% |
| 12/13 | 336 | 339 | 331 | 333 | -2.06% | 138,500 | 85億1064万 | -17.78% |
| 12/12 | 350 | 350 | 337 | 340 | -1.45% | 95,200 | 86億8955万 | -16.87% |
| 12/11 | 350 | 358 | 345 | 345 | -0.29% | 89,200 | 88億1733万 | -16.67% |
| 12/08 | 360 | 361 | 346 | 346 | -5.46% | 156,700 | 88億4289万 | -17.03% |
| 12/07 | 381 | 381 | 361 | 366 | -4.94% | 178,100 | 93億5404万 | -12.86% |
| 12/06 | 395 | 396 | 383 | 385 | -2.78% | 149,600 | 98億3963万 | -8.98% |
| 12/05 | 404 | 407 | 396 | 396 | -2.94% | 68,500 | 101億2077万 | -6.82% |
| 12/04 | 408 | 408 | 402 | 408 | -0.73% | 22,600 | 104億2746万 | -4.23% |
| 12/01 | 412 | 412 | 405 | 411 | -0.48% | 40,500 | 105億413万 | -3.52% |
| 11/30 | 404 | 415 | 403 | 413 | +1.98% | 60,100 | 105億5524万 | -3.28% |
